CIP2A: A Potential Drug Target and Biomarker (G57650)

Target Name: CIP2A

NCBI ID: G57650

CIP2A

CIP2A: A Potential Drug Target and Biomarker

CIP2A, also known as FLJ12850, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the families of cytoskeletal proteins, which are involved in the structure and function of cells . CIP2A is unique because it is a transmembrane protein, meaning it spans the membrane of the cell. This property makes it an attractive target for drug development because it allows for targeted delivery of drugs to the cell.

CIP2A functions as a negative regulator of the protein kinase B-Raf-MEK-ERK signaling pathway. This pathway is involved in many cellular processes, including cell growth, differentiation, and survival. CIP2A helps to regulate the activity of this pathway by blocking the ability of MEK to phosphorylate and activate B-Raf. This inhibition of MEK activity inhibits the signaling pathway that regulates cell growth and survival.

CIP2A is also involved in the regulation of the cytoskeleton. It helps to maintain the integrity of the cytoskeleton by interacting with microtubules and preventing their disruption. This interaction between CIP2A and microtubules is important for the proper functioning of cells, including the development and maintenance of tissues and organs.

CIP2A is a potential drug target because of its involvement in the regulation of the B-Raf-MEK-ERK signaling pathway and its role in the regulation of the cytoskeleton. Drugs that target this pathway or its regulators have been shown to be effective in treating a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CIP2A is also a potential biomarker for some diseases. Its involvement in the regulation of the B-Raf-MEK-ERK signaling pathway makes it an attractive target for diagnostic tests for diseases that are associated with this pathway. For example, CIP2A has been shown to be downregulated in many types of cancer, including breast, ovarian, and prostate cancer. This downregulation is thought to contribute to the development and progression of these diseases. Therefore, CIP2A levels can be used as a biomarker for the diagnosis and prognosis of these diseases. cancers.

In addition to its potential as a drug target and biomarker, CIP2A is also a valuable tool for the study of cellular signaling pathways. Its ability to span the membrane of cells and its role in regulating the cytoskeleton make it an interesting model for study in the laboratory. Researchers can use techniques such as immunofluorescence and biochemical assays to study the localization and activity of CIP2A in different cellular contexts.

Overall, CIP2A is a protein that is involved in many important cellular processes and functions. Its unique property as a transmembrane protein and its involvement in the regulation of the B-Raf-MEK-ERK signaling pathway make it an attractive target for drug development . Its involvement in the regulation of the cytoskeleton also makes it a potential biomarker for the diagnosis and prognosis of many diseases. Further research is needed to fully understand the role of CIP2A in these processes and to develop effective treatments.

Protein Name: Cellular Inhibitor Of PP2A

Functions: Oncoprotein that inhibits PP2A and stabilizes MYC in human malignancies. Promotes anchorage-independent cell growth and tumor formation

The "CIP2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIP2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets